Paulson & CO. Inc. cut its position in DexCom, Inc. (NASDAQ:DXCM) by 17.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 240,700 shares of the medical device company’s stock after selling 52,500 shares during the period. Paulson & CO. Inc.’s holdings in DexCom were worth $20,395,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in DXCM. BlackRock Inc. increased its position in DexCom by 5,000.4% in the first quarter. BlackRock Inc. now owns 4,160,862 shares of the medical device company’s stock worth $352,550,000 after buying an additional 4,079,283 shares during the period. Bank of New York Mellon Corp increased its position in DexCom by 304.3% in the first quarter. Bank of New York Mellon Corp now owns 2,546,729 shares of the medical device company’s stock worth $215,785,000 after buying an additional 1,916,759 shares during the period. Janus Capital Management LLC increased its position in DexCom by 99.7% in the fourth quarter. Janus Capital Management LLC now owns 3,565,809 shares of the medical device company’s stock worth $213,021,000 after buying an additional 1,779,973 shares during the period. FMR LLC increased its position in DexCom by 9.1% in the first quarter. FMR LLC now owns 9,845,408 shares of the medical device company’s stock worth $834,201,000 after buying an additional 823,406 shares during the period. Finally, Fred Alger Management Inc. increased its position in DexCom by 48.9% in the fourth quarter. Fred Alger Management Inc. now owns 2,469,482 shares of the medical device company’s stock worth $147,428,000 after buying an additional 811,062 shares during the period.
Shares of DexCom, Inc. (NASDAQ:DXCM) traded up 0.86% on Friday, hitting $76.26. The stock had a trading volume of 1,835,042 shares. The firm’s 50-day moving average is $71.44 and its 200 day moving average is $73.83. The stock’s market cap is $6.59 billion. DexCom, Inc. has a 1-year low of $57.68 and a 1-year high of $96.38.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.06. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. The business had revenue of $142.30 million during the quarter, compared to analysts’ expectations of $143.94 million. Equities analysts forecast that DexCom, Inc. will post ($0.70) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by sleekmoney and is the property of of sleekmoney. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://sleekmoney.com/paulson-co-inc-has-20-40-million-stake-in-dexcom-inc-dxcm/1916229.html.
DXCM has been the topic of a number of research reports. Cowen and Company restated an “outperform” rating and issued a $90.00 price objective on shares of DexCom in a report on Tuesday, April 18th. BTIG Research downgraded DexCom from a “buy” rating to a “neutral” rating in a report on Wednesday, May 3rd. William Blair restated an “outperform” rating on shares of DexCom in a report on Thursday, April 27th. Jefferies Group LLC cut their price objective on DexCom to $91.00 and set a “buy” rating on the stock in a report on Tuesday, May 9th. Finally, Canaccord Genuity cut their price objective on DexCom from $95.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, May 3rd. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $90.44.
In related news, CFO Jess Roper sold 2,000 shares of the business’s stock in a transaction dated Wednesday, March 22nd. The stock was sold at an average price of $75.97, for a total transaction of $151,940.00. Following the transaction, the chief financial officer now directly owns 46,497 shares in the company, valued at $3,532,377.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Terrance H. Gregg sold 15,000 shares of the business’s stock in a transaction dated Thursday, April 20th. The shares were sold at an average price of $74.10, for a total value of $1,111,500.00. Following the transaction, the insider now owns 454,559 shares in the company, valued at $33,682,821.90. The disclosure for this sale can be found here. Insiders have sold a total of 60,795 shares of company stock valued at $4,428,513 in the last three months. 1.70% of the stock is owned by insiders.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/paulson-co-inc-has-20-40-million-stake-in-dexcom-inc-dxcm/1916229.html
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.